U.S. Army Deploys Rapid Prototyping Labs to Afghanistan
The U.S. Army has deployed a number of rapid prototyping labs into Afghanistan. The labs are packed into standard 20-foot shipping containers, each with their own generator and method of climate control. The $2.8 million worth of goodies stuffed inside each container includes 3D Printers and CNC Machines as well as plasma cutters, welders, magnetic mounted drill-presses, electric hacksaws, routers, circular saws and jig saws.
The labs are part of the Army's continuing effort to meet the immediate needs of front-line soldiers. "It's really difficult to connect the guy who is building the product to the kid who really needed it to begin with, so what we went after is to connect the scientist to the soldier," said Col. Pete Newell, commander of the Army's Rapid Equipping Force at Fort Belvoir, Va. "Rather than bringing the soldier home to the scientist, we have uprooted the scientist and the engineer and brought them to the soldier."
Each development pod does come complete with a senior scientist and an assistant, ready to take on the requests of G.I.'s in the field. With the prototyping equipment at their fingertips they can turn around a usable product within a matter of days. If the deployed scientists can't find a way to make what the soldiers need, they can connect to a network of 6,000 other military engineers who are ready to lend a hand.
Col. Newell also stated that in the future labs of this type could be used in disaster relief efforts. Being able to drop a pod after Hurricane Katrina for example, could have helped a lot of people. One thing is for certain though; the Army is so happy with the performance of the mobile development labs they plan to use them long past 2014, when our soldiers are scheduled to come home from Afghanistan.
Boehringer Ingelheim receives FDA cancer drugs afatinib quick review of eligibility
ReplyDeleteThe FDA has decided to afatinib pharmaceutical company Boehringer Ingelheim for quick review, afatinib is the company first filed in the U.S. oncology drugs. This means, FDA will decide whether to approve afatinib.
Afatinib is an orphan drug for the treatment with epidermal growth factor receptor (EGFR) mutations in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).
Application is based lux lung cancer clinical trial program data, the data show afatinib relative to chemotherapy drugs have an "unprecedented efficacy." The study will afatinib lung cancer patients with the best kind of chemotherapy (pemetrexed and cisplatin) for comparison. Afatinib accepted as first-line therapy in patients with tumor progression-free survival for an average of 11.1 months, while taking other chemotherapy drugs progression-free survival in patients with an average of 6.9 months, showing afatinib potential effect. The project data is further supported by the drug in Europe in September last year's application.
Boehringer Ingelheim Pharmaceuticals, Inc., vice president and business unit leader Kevin Lokay commented that, "based on the acceptance of afatinib applications, as well as in the development of tumors in our products, we will continue to promote the establishment of a world-class business organization tumor plan."
Medchemexpress Can provide the above product,its website:www.medchemexpress.com
Enzalutamide
TOK-001
Anastrozole
GSK1292263
TAK-875
Andarine
Maraviroc
Dolutegravir
Elvitegravir
HIV-1 integrase inhibitor 2